Literature DB >> 8422430

Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1.

Y Labelle1, J Puymirat, R M Tanguay.   

Abstract

Fumarylacetoacetate hydrolase (FAH) is the terminal enzyme in the catabolic pathway of tyrosine. This enzyme which is mainly expressed in the liver and kidney is deficient in hereditary tyrosinemia type 1. As some affected individuals present neurologic abnormalities, we studied the expression of FAH in the rat and human brain. The FAH gene was shown to be expressed in the rat brain by immunoblot and Northern blot analysis. The FAH protein was also detected in human brain by the immunoblot assay. An immunohistochemical study was undertaken to localize the FAH-producing cells in the rat central nervous system. This analysis showed that the majority of FAH-producing cells are localized in the axonal nerve fibers of the white matter, although positive cells could also be found throughout the brain. The greatest number of FAH-positive cells were found in structures consisting essentially of white matter, such as the corpus callosum. This specific localization in the white matter indicates that some type of glial cells are responsible for the expression of the FAH protein in the rat central nervous system. The characteristic linear organization found in some of the FAH-positive cells in the corpus callosum suggests that these glial cells are oligodendrocytes. These findings are discussed with respect to the neurologic symptoms observed in some tyrosinemia patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422430     DOI: 10.1016/0925-4439(93)90046-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  The repopulation potential of hepatocyte populations differing in size and prior mitotic expansion.

Authors:  K Overturf; M Al-Dhalimy; M Finegold; M Grompe
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Abnormal social behavior in mice with tyrosinemia type I is associated with an increase of myelin in the cerebral cortex.

Authors:  Marissa E Moore; Ashton E Koenig; Megan A Hillgartner; Christopher C Otap; Elizabeth Barnby; Gordon G MacGregor
Journal:  Metab Brain Dis       Date:  2017-07-15       Impact factor: 3.584

3.  Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice.

Authors:  Megan A Hillgartner; Sarah B Coker; Ashton E Koenig; Marissa E Moore; Elizabeth Barnby; Gordon G MacGregor
Journal:  J Inherit Metab Dis       Date:  2016-06-06       Impact factor: 4.982

4.  Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: kinetics, crystal structure and pharmacokinetics.

Authors:  Raynard L Bateman; Justin Ashworth; John F Witte; L-J Baker; Pullooru Bhanumoorthy; David E Timm; Thomas D Hurley; Markus Grompe; Ronald W McClard
Journal:  Biochem J       Date:  2007-03-01       Impact factor: 3.857

5.  Loss of p27(Kip1) enhances the transplantation efficiency of hepatocytes transferred into diseased livers.

Authors:  A N Karnezis; M Dorokhov; M Grompe; L Zhu
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

6.  Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes.

Authors:  K Overturf; M al-Dhalimy; C N Ou; M Finegold; M Grompe
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.